Nurix Enrolls First Patient in Head-to-Head Phase 3 for Bexobrutideg

Company: Nurix Therapeutics (with Roche) · Event Type: Pivotal Trial Initiation · Modality: BTK-Targeted Protein Degrader · Asset: Bexobrutideg (NX-5948) · Indication: Relapsed/Refractory CLL/SLL · Comparator: Pirtobrutinib Summary Nurix Therapeutics enrolled the first participant in DAYBreak CLL-306, a global randomized Phase III trial comparing the…